Omics! Omics!

A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery

Tuesday, May 31, 2022

Ultima Genomics Storms Out Of Stealth Promising $1/Gigabase Short Reads

›
To date, the new entrants targeting Illumina’s short read business have been aiming at the middle of Illumina’s range, trying to take on Nex...
7 comments:
Monday, May 23, 2022

London Calling 2022: Peptide Sequencing

›
London Calling was last week and Clive Brown's big revelation was a peek at Oxford Nanopore's progress on enabling peptide sequencin...
Friday, April 15, 2022

Nanopore Knights' Notes

›
Clive Brown gave a "mezzanine" update on Oxford Nanopore just over two weeks ago titled "The Knights Who Say Me".  Clive...
2 comments:
Thursday, March 31, 2022

The End of the Beginning of Human Genome Sequencing?

›
Today in Science  a slew of papers have been published from the Telomere-to-Telomere (T2T) Consortium.  The flagship paper details the gener...
2 comments:
Monday, March 14, 2022

Element Unveils AVITI

›
Element Biosciences is launching their AVITI sequencing system today in a blitz of events.  At February’s end they flew me out to visit thei...
4 comments:
Thursday, February 17, 2022

Pro Tip: Customer Hostile is Never A Good Look

›
A bizarre incident happened on Twitter yesterday.  Someone contemplating using Oxford Nanopore to sequence a large, complex genome on a tigh...
8 comments:
Tuesday, February 15, 2022

Parse Bio Pools Further Funding

›
Seattle-based single cell analysis firm Parse Bio is announcing this morning a $41.5M Series B round of funding, pushing their total raise j...
Monday, January 31, 2022

Notes from a Conversation with PacBio's Christian Henry

›
PacBio CEO Christian Henry was kind enough to chat with me by videoconference just after JP Morgan.  To get the the obvious issue out of the...
1 comment:
Monday, January 17, 2022

Could Hercule Poirot Crack The Case of Genapsys' Business Strategy?

›
If you love a good mystery, let me try to draw you in to the enigma of Genapsys' business strategy.  Genapsys presented last week at J.P...
1 comment:
Wednesday, January 12, 2022

Illumina Teases Two Glittering Enigmas

›
Illumina's J.P. Morgan presentation was largely focused on various applications of their platform.  But on the further platform developm...
3 comments:
Tuesday, January 11, 2022

Apologies & A Vow To Do Better

›
To my readers: I am quite embarrassed by the multiple errors which were present in the first two postings of the year, which include incompl...
3 comments:
Thursday, January 06, 2022

Three Reactions from December's PacBio+Invitae Mendelspod

›
Theral Timpson hosted PacBio CEO Christian Henry and Invitae CEO Sean George for a Mendelspod podcast  back on Pearl Harbor day last month ....
5 comments:
Monday, January 03, 2022

2022: A Wild Year for Short Reads?

›
It looks like 2022 might be an exciting year for the short read genomics market, with new players taking on Illumina.  J.P. Morgan will be v...
5 comments:
Friday, December 31, 2021

Reflecting on Anniversaries and Changes

›
As the year closes out for me (as I write this, it may well have closed out for some of you!) I'm reflecting on some anniversaries that ...
2 comments:
Monday, December 13, 2021

ONT Community Meeting 2021

›
Oxford Nanopore held their annual Community Meeting online at the beginning of this month.  As is typical for this stage of the ONT news cyc...
Tuesday, October 26, 2021

A Look at Two HiFi Polisher Preprints

›
PacBio has made its reputation delivering very high accuracy long reads, which they have branded HiFi. These are based on their circular con...
Wednesday, August 04, 2021

PacBio Pulls Down Circulomics

›
I was on vacation early this week when the news broke that PacBio has acquired HMW DNA solid phase extraction kit maker Circulomics -- the k...
Tuesday, July 20, 2021

PacBio Enters a Binding Agreement to Acquire Omniome

›
Pacific Biosciences announced today that they are slurping up short read sequencer startup Omniome for around $800M.  Omniome has been devel...
11 comments:
Tuesday, June 29, 2021

ONT Sketches Paths to Long, Selective, Accurate Sequencing

›
Some sort of summary of London Calling in this space is grossly overdue after getting caught by multiple work firedrills and then several re...
5 comments:
Wednesday, June 02, 2021

New Clinical Human Genome Speed Record

›
I proposed last year that there should be a regular racing event for human genomics.  The only real competitor in is this interesting race ...
1 comment:
‹
›
Home
View web version

About Me

My photo
Keith Robison
Dr. Robison spent 10 years at Millennium Pharmaceuticals working with various genomics & proteomics technologies & working on multiple teams attempting to apply these throughout the drug discovery process. He spent 2 years at Codon Devices working on a variety of protein & metabolic engineering projects as well as monitoring a high-throughput gene synthesis facility. After a brief bit of consulting, he rejoined the cancer drug discovery field at Infinity Pharmaceuticals in May 2009. In September 2011 he joined Warp Drive Bio, a startup applying genomics to natural product drug discovery. In February 2019 he joined Ginkgo Bioworks, a synthetic biology company. Other recurring characters in this blog are his late loyal Shih Tzu Amanda, his current Shih Poo Lily and his now adult son alias TNG (The Next Generation). Dr. Robison can be reached via his Gmail account, keith.e.robison@gmail.com You can also follow him on Twitter as @OmicsOmicsBlog.
View my complete profile
Powered by Blogger.